Clinical Trial Update: A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 study of KHK4827 in moderate-to-severe systemic sclerosis has completed. The update does not include efficacy or safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• KHK4827

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Moderate to Severe Systemic Sclerosis | Phase 3 | Status: COMPLETED